Trials / Unknown
UnknownNCT04331743
A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC
A Single-arm, Open-label, Single-center Phase Ib Study to Evaluate the Safety and Efficacy of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Advanced Hepatocellular Carcinoma (HCC)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose escalation study based on 3+3 design with the aim to establish MTD and provide RP2D. PLM60 is to administered by multi-cycle intravenous infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liposome-entrapped Mitoxantrone Hydrochloride Injection | Intravenous infusion |
Timeline
- Start date
- 2021-06-05
- Primary completion
- 2023-05-15
- Completion
- 2023-06-01
- First posted
- 2020-04-02
- Last updated
- 2021-06-16
Source: ClinicalTrials.gov record NCT04331743. Inclusion in this directory is not an endorsement.